What Can We Apply to Manage Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Respiratory Failure?.
- Author:
Deog Kyeom KIM
1
;
Jungsil LEE
;
Ju Hee PARK
;
Kwang Ha YOO
Author Information
- Publication Type:Review
- Keywords: Pulmonary Disease, Chronic Obstructive; Respiratory Insufficiency; Noninvasive Ventilation; Oxygen Inhalation Therapy; Carbon Dioxide
- MeSH: Anti-Bacterial Agents; Bronchodilator Agents; Carbon Dioxide; Catheters; Head Protective Devices; Humans; Intubation; Mortality; Noninvasive Ventilation; Oxygen; Oxygen Inhalation Therapy; Prognosis; Pulmonary Disease, Chronic Obstructive*; Respiration, Artificial; Respiratory Distress Syndrome, Adult; Respiratory Insufficiency*; Steroids
- From:Tuberculosis and Respiratory Diseases 2018;81(2):99-105
- CountryRepublic of Korea
- Language:English
- Abstract: Acute exacerbation(s) of chronic obstructive pulmonary disease (AECOPD) tend to be critical and debilitating events leading to poorer outcomes in relation to chronic obstructive pulmonary disease (COPD) treatment modalities, and contribute to a higher and earlier mortality rate in COPD patients. Besides pro-active preventative measures intended to obviate acquisition of AECOPD, early recovery from severe AECOPD is an important issue in determining the long-term prognosis of patients diagnosed with COPD. Updated GOLD guidelines and recently published American Thoracic Society/European Respiratory Society clinical recommendations emphasize the importance of use of pharmacologic treatment including bronchodilators, systemic steroids and/or antibiotics. As a non-pharmacologic strategy to combat the effects of AECOPD, noninvasive ventilation (NIV) is recommended as the treatment of choice as this therapy is thought to be most effective in reducing intubation risk in patients diagnosed with AECOPD with acute respiratory failure. Recently, a few adjunctive modalities, including NIV with helmet and helium-oxygen mixture, have been tried in cases of AECOPD with respiratory failure. As yet, insufficient documentation exists to permit recommendation of this therapy without qualification. Although there are too few findings, as yet, to allow for regular andr routine application of those modalities in AECOPD, there is anecdotal evidence to indicate both mechanical and physiological benefits connected with this therapy. High-flow nasal cannula oxygen therapy is another supportive strategy which serves to improve the symptoms of hypoxic respiratory failure. The therapy also produced improvement in ventilatory variables, and it may be successfully applied in cases of hypercapnic respiratory failure. Extracorporeal carbon dioxide removal has been successfully attempted in cases of adult respiratory distress syndrome, with protective hypercapnic ventilatory strategy. Nowadays, it is reported that it was also effective in reducing intubation in AECOPD with hypercapnic respiratory failure. Despite the apparent need for more supporting evidence, efforts to improve efficacy of NIV have continued unabated. It is anticipated that these efforts will, over time, serve toprogressively decrease the risk of intubation and invasive mechanical ventilation in cases of AECOPD with acute respiratory failure.
